$14.27 -0.18 (-1.25%)
12/3/2009 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating: 4 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Recs

0
Member Avatar TMFBreakerJava (98.23) Submitted: 9/5/2008 1:04:04 AM : Outperform Start Price: $21.12 AMLN Score: -24.81

Promising results for Byetta offer the prospect of a better drug for diabetes. A potential blockbuster at a knockdown price. Buy!

Report this Post 0 Comments

Featured Broker Partners